The DOI matches its Crossref record.
Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial
Open accessAbstract
Purpose: Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD). However, in most patients, chemotherapy cannot be discontinued. Patients and Methods: To evaluate the efficacy of four weekly rituximab infusions (375 mg/m 2) after discontinuation of chemotherapy in HIV-associated MCD, 24 patients were enrolled onto a prospective open-label trial. Results: At study entry, the median time from MCD diagnosis was 21 months. All patients had stable disease on chemotherapy and were dependent on chemotherapy for a median time of 13 months. The median CD4 cell count was 270 × 10 6/L, and the plasma HIV RNA was less than 50 copies/mL in 18 patients. One patient died with progressive disease at day 15, and 23 patients completed the four cycles of rituximab. Sustained remission (SR) off treatment at day 60 (primary end point) was achieved in 22 patients (92%). From day 60 to day 365, one patient died with acute respiratory failure of undetermined origin, and four patients experienced relapse. Seventeen patients (71%) were alive in SR at day 365 without specific treatment, and the overall survival rate was 92% (95% CI, 71% to 98%). Rituximab was well tolerated, and the majority of adverse events were mild to moderate infections. Mild exacerbation of Kaposi's sarcoma (KS) lesions was observed in eight of 12 patients with previous KS. Conclusion: Rituximab was both effective and safe in HIV-infected patients with chemotherapy-dependent MCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
HIV-Associated Cancers and Related Diseases
Yarchoan, R., & Uldrick, T. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1615896 · Cited by 521
Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487
Idiopathic multicentric Castleman's disease: a systematic literature review
Liu, A. Y., Nabel, C. S., Finkelman, B. S., Ruth, J. R., Kurzrock, R., van Rhee, F., Krymskaya, V. P., Kelleher, D., Rubenstein, A. H., & Fajgenbaum, D. C. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00006-5 · Cited by 330
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Metadata
- Authors
- Gérard, L., Bérezné, A., Galicier, L., Meignin, V., Obadia, M., De Castro, N., Jacomet, C., Verdon, R., Madelaine-Chambrin, I., Boulanger, E., Chevret, S., Agbalika, F., & Oksenhendler, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-08-01
- Volume
- 25
- Issue
- 22
- Pages
- 3350-3356
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156787162
- Cited by
- 235
- References
- 0
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial. https://app.cochat.ai/papers/10.1200/jco.2007.10.6732
- The paper
- Gérard, L., Bérezné, A., Galicier, L., Meignin, V., Obadia, M., De Castro, N., Jacomet, C., Verdon, R., Madelaine-Chambrin, I., Boulanger, E., Chevret, S., Agbalika, F., & Oksenhendler, E. (2007). Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.10.6732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.